Business Description
Tandem Diabetes Care Inc
NAICS : 339112
SIC : 3841
ISIN : US8753722037
Total Employee Number:
2,500Description
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.78 | |||||
Equity-to-Asset | 0.12 | |||||
Debt-to-Equity | 5.55 | |||||
Debt-to-EBITDA | -9.96 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 0.4 | |||||
Beneish M-Score | -2.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.5 | |||||
3-Year EBITDA Growth Rate | -31.4 | |||||
3-Year EPS without NRI Growth Rate | -24 | |||||
3-Year Book Growth Rate | -30.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.72 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.72 | |||||
9-Day RSI | 55.59 | |||||
14-Day RSI | 51.24 | |||||
3-1 Month Momentum % | -16.38 | |||||
6-1 Month Momentum % | -19.69 | |||||
12-1 Month Momentum % | 6.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.58 | |||||
Quick Ratio | 3.07 | |||||
Cash Ratio | 2.3 | |||||
Days Inventory | 106.58 | |||||
Days Sales Outstanding | 48.81 | |||||
Days Payable | 42.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | -3.54 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.93 | |||||
Operating Margin % | -6.22 | |||||
Net Margin % | -9.2 | |||||
EBITDA Margin % | -7.18 | |||||
FCF Margin % | -3.77 | |||||
OCF Margin % | 1.91 | |||||
ROE % | -66.67 | |||||
ROA % | -10.04 | |||||
ROIC % | -12.36 | |||||
3-Year ROIIC % | -49.7 | |||||
ROC (Joel Greenblatt) % | -35.65 | |||||
ROCE % | -13.38 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.07 | |||||
PB Ratio | 8.41 | |||||
Price-to-Tangible-Book | 8.41 | |||||
Price-to-Operating-Cash-Flow | 56.82 | |||||
EV-to-EBIT | -13.95 | |||||
EV-to-Forward-EBIT | -12.63 | |||||
EV-to-EBITDA | -17.33 | |||||
EV-to-Forward-EBITDA | -17.49 | |||||
EV-to-Revenue | 1.24 | |||||
EV-to-Forward-Revenue | 1.14 | |||||
EV-to-FCF | -32.97 | |||||
Price-to-GF-Value | 0.54 | |||||
Price-to-Median-PS-Value | 0.34 | |||||
Earnings Yield (Greenblatt) % | -7.17 | |||||
FCF Yield % | -3.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tandem Diabetes Care Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,027.535 | ||
| EPS (TTM) ($) | -1.4 | ||
| Beta | 3.6394 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.2 | ||
| Volatility % | 80.04 | ||
| 14-Day RSI | 51.24 | ||
| 14-Day ATR ($) | 0.807452 | ||
| 20-Day SMA ($) | 15.529175 | ||
| 12-1 Month Momentum % | 6.31 | ||
| 52-Week Range ($) | 10.025 - 29.47 | ||
| Shares Outstanding (Mil) | 68.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tandem Diabetes Care Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tandem Diabetes Care Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | In 24 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 23 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 15:20 | 20.43 (+7.20%) | ||
| General meeting for 2026 | 2026-05-20 15:00 | 13.80 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-12 17:20 | 14.97 (-1.51%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 18.16 (-8.95%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 18.16 (-8.95%) | ||
| Oppenheimer 36 Annual Healthcare MedTech & Services Conference | 2026-03-18 13:20 | 23.90 (+5.29%) |
Show
Entries
Tandem Diabetes Care Inc Frequently Asked Questions
What is Tandem Diabetes Care Inc(LTS:0M0F)'s stock price today?
The current price of LTS:0M0F is $16.06. The 52 week high of LTS:0M0F is $29.47 and 52 week low is $10.03.
When is next earnings date of Tandem Diabetes Care Inc(LTS:0M0F)?
The next earnings date of Tandem Diabetes Care Inc(LTS:0M0F) is 2026-08-06.
Does Tandem Diabetes Care Inc(LTS:0M0F) pay dividends? If so, how much?
Tandem Diabetes Care Inc(LTS:0M0F) does not pay dividend.
Press Release
Articles on Tandem Diabetes Care Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers